Pyxis Oncology (PYXS) Share-based Compensation (2020 - 2025)

Pyxis Oncology (PYXS) has 6 years of Share-based Compensation data on file, last reported at -$9.6 million in Q4 2025.

• On a quarterly basis, Share-based Compensation fell 445.15% year-over-year to -$9.6 million in Q4 2025; TTM through Dec 2025 was $6.0 million, a 69.81% decrease from a year earlier, with the FY2025 full-year figure at $6.0 million, down 53.65% from the prior year.
• Share-based Compensation for Q4 2025 stood at -$9.6 million, down from $6.5 million in the prior quarter.
• Over the last five years, Share-based Compensation for PYXS reached as high as $11.0 million in Q1 2025 and fell as low as -$9.6 million in Q4 2025.
• Historically, Share-based Compensation has averaged $3.6 million across 5 years, with a median of $3.3 million in 2022.
• Across the five-year window, Share-based Compensation surged 27763.64% in 2021 and plunged 445.15% in 2025, its largest moves.
• Year by year, Share-based Compensation stood at $3.0 million in 2021, then gained by 28.1% to $3.9 million in 2022, then retreated by 17.52% to $3.2 million in 2023, then declined by 13.75% to $2.8 million in 2024, then plunged by 445.15% to -$9.6 million in 2025.
• Per Business Quant data, the three most recent Share-based Compensation figures were -$9.6 million in Q4 2025, $6.5 million in Q3 2025, and $8.3 million in Q2 2025.